A dwindling COVID-19 vaccine market is not stopping Arcturus Therapeutics from pressing ahead with its own mRNA candidate, as the biotech touts new early data indicating its shot lights up the immune ...
ROCHESTER, N.Y. — What’s the guidance for the new COVID-19 subvariant? The variant has been dubbed Arcturus and it’s similar to the other Omicron subvariants that came before it. The new variant ...
Arcturus Therapeutics Holdings Inc. reported that ARCT-154, its self-amplifying mRNA COVID-19 vaccine, showed efficacy of 55% against infection and 95% efficacy against severe disease, meeting the ...
KING OF PRUSSIA, Pa. and SAN DIEGO, Feb. 5, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and Arcturus Therapeutics (ARCT) today announced the results of a follow-up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results